Client: 600 CPK LLC
Location: Northbridge, MA
EyePoint Pharmaceuticals brings hope to people with serious eye disease by developing new treatments and drug-delivery systems for many challenging conditions, including macular degeneration, the leading cause of vision loss among adults.
New cGMP Manufacturing Facility
Making medicine for people is among the most tightly regulated manufacturing processes. RP Masiello was pleased to be selected by the developer 600 CPK LLC and EyePoint to lead the design/build effort for a 40,000 sq. ft. manufacturing facility that will conform to the rigorous requirements of current Good Manufacturing Practices (cGMP) and allow EyePoint to meet U.S. FDA and European Medicines Agency (EMA) standards for producing therapeutics.
EyePoint’s new facility will be customized for their specific development and manufacturing programs. It will include 10 production suites for clinical supply and commercial scale manufacturing of approved products, plus laboratory support space, all built to ISO 7 clean room standards. The facility will accommodate Quality Control and Quality Assurance (QC/QA) functions and administrative spaces to support continue growth of their global business.
Construction is underway, with completion expected in 2024.